Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski, Christophe Hezode, Jan Gerstoft, John M Vierling, Josep Mallolas, Stanislas Pol, Marcelo Kugelmas, Abel Murillo, Nina Weis, Ronald Nahass, Oren Shibolet, Lawrence Serfaty, Marc Bourliere, Edwin DeJesus, Eli Zuckerman, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita Y M Howe, Janice WahlMichael Robertson, Eliav Barr, Barbara Haber
Dyk ned i forskningsemnerne om 'Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial'. Sammen danner de et unikt fingeraftryk.